APA (7th ed.) Citation

Uzor, S., Porazinski, S. R., Li, L., Clark, B., Ajiro, M., Iida, K., . . . Ladomery, M. R. (2021). CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer. Scientific reports, 11(1), 7963-12. https://doi.org/10.1038/s41598-021-86908-6

Chicago Style (17th ed.) Citation

Uzor, Simon, et al. "CDC2-like (CLK) Protein Kinase Inhibition as a Novel Targeted Therapeutic Strategy in Prostate Cancer." Scientific Reports 11, no. 1 (2021): 7963-12. https://doi.org/10.1038/s41598-021-86908-6.

MLA (9th ed.) Citation

Uzor, Simon, et al. "CDC2-like (CLK) Protein Kinase Inhibition as a Novel Targeted Therapeutic Strategy in Prostate Cancer." Scientific Reports, vol. 11, no. 1, 2021, pp. 7963-12, https://doi.org/10.1038/s41598-021-86908-6.